FDA Official Vinay Prasad To Exit As Trump Team Weighs Replacement

reviews, including decisions tied to COVID-19 vaccines, gene therapies and treatments for rare diseases. Those disagreements sometimes played out publicly, adding to scrutiny surrounding the FDA’s internal decision-making process.

The Trump administration is now considering Houman Hemmati to lead the FDA’s Center for Biologics Evaluation and Research

according continue reading …